Literature DB >> 16159808

Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials.

Dongming Hou1, Eyas Al-Shaykh Youssef, Todd J Brinton, Ping Zhang, Pamela Rogers, Erik T Price, Alan C Yeung, Brian H Johnstone, Paul G Yock, Keith L March.   

Abstract

BACKGROUND: Several clinical studies are evaluating the therapeutic potential of delivery of various progenitor cells for treatment of injured hearts. However, the actual fate of delivered cells has not been thoroughly assessed for any cell type. We evaluated the short-term fate of peripheral blood mononuclear cells (PBMNCs) after intramyocardial (IM), intracoronary (IC), and interstitial retrograde coronary venous (IRV) delivery in an ischemic swine model. METHODS AND
RESULTS: Myocardial ischemia was created by 45 minutes of balloon occlusion of the left anterior descending coronary artery. Six days later, 10(7) 111indium-oxine-labeled human PBMNCs were delivered by IC (n=5), IM (n=6), or IRV (n=5) injection. The distribution of injected cells was assessed by gamma-emission counting of harvested organs. For each delivery method, a significant fraction of delivered cells exited the heart into the pulmonary circulation, with 26+/-3% (IM), 47+/-1% (IC), and 43+/-3% (IRV) of cells found localized in the lungs. Within the myocardium, significantly more cells were retained after IM injection (11+/-3%) compared with IC (2.6+/-0.3%) (P<0.05) delivery. IRV delivery efficiency (3.2+/-1%) trended lower than IM infusion for PBMNCs, but this difference did not reach significance. The IM technique displayed the greatest variability in delivery efficiency by comparison with the other techniques.
CONCLUSIONS: The majority of delivered cells is not retained in the heart for each delivery modality. The clinical implications of these findings are potentially significant, because cells with proangiogenic or other therapeutic effects could conceivably have effects in other organs to which they are not primarily targeted but to which they are distributed. Also, we found that although IM injection was more efficient, it was less consistent in the delivery of PBMNCs compared with IC and IRV techniques.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159808     DOI: 10.1161/CIRCULATIONAHA.104.526749

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  232 in total

1.  Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.

Authors:  Qianhong Li; Yiru Guo; Qinghui Ou; Ning Chen; Wen-Jian Wu; Fangping Yuan; Erin O'Brien; Tao Wang; Li Luo; Gregory N Hunt; Xiaoping Zhu; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-04-24       Impact factor: 17.165

2.  Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion.

Authors:  Ke Cheng; Konstantinos Malliaras; Tao-Sheng Li; Baiming Sun; Christiane Houde; Giselle Galang; Jeremy Smith; Noriko Matsushita; Eduardo Marbán
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

Review 3.  Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction.

Authors:  Jay H Traverse
Journal:  J Cardiovasc Transl Res       Date:  2011-11-17       Impact factor: 4.132

Review 4.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 5.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

Review 6.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

Review 7.  The paracrine effect: pivotal mechanism in cell-based cardiac repair.

Authors:  Simon Maltais; Jacques P Tremblay; Louis P Perrault; Hung Q Ly
Journal:  J Cardiovasc Transl Res       Date:  2010-06-08       Impact factor: 4.132

8.  Optimized delivery system achieves enhanced endomyocardial stem cell retention.

Authors:  Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic
Journal:  Circ Cardiovasc Interv       Date:  2013-12-10       Impact factor: 6.546

9.  Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage.

Authors:  Hirotsugu Hamamoto; Joseph H Gorman; Liam P Ryan; Robin Hinmon; Timothy P Martens; Michael D Schuster; Theodore Plappert; Matti Kiupel; Martin G St John-Sutton; Silviu Itescu; Robert C Gorman
Journal:  Ann Thorac Surg       Date:  2009-03       Impact factor: 4.330

Review 10.  Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.

Authors:  Patricia K Nguyen; Evgenios Neofytou; June-Wha Rhee; Joseph C Wu
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.